Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Recruiting now · Not applicable

Conditions studied: Soft Tissue Sarcoma, Clear Cell Sarcoma, Epithelioid Sarcoma, Perivascular Epithelioid Cell Neoplasms, Desmoplastic Small Round Cell Tumor, Malignant Solitary Fibrous Tumors, Alveolar Soft Part Sarcoma, Epithelioid Hemangioendothelioma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma

In brief

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).

Key facts

Study ID

NCT03967834

Run by

Institut Claudius Regaud

People needed

400

Starts

2021-04-26

Expected to finish

2031-04-01

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years at the time of study entry.
• Diagnosis of one of the following rare sarcoma subtype, confirmed by RRePS network:
• Clear Cell Sarcoma (CCS)
• Epithelioid Sarcoma (ES)
• Perivascular Epithelioid Cell neoplasm (PEComa)
• Desmoplastic Small Round Cell Tumours (DSRCT)
• Malignant Solitary Fibrous Tumours (mSFT)
• Alveolar Soft Part Sarcoma (ASPS)
• Epithelioid Hemangioendothelioma (EH)
• Low-Grade Fibromyxoid Sarcoma (LGFS)
• Sclerosing Epithelioid Fibrosarcoma (SEF).
• Localized/locally advanced or metastatic disease.
• In case of localized disease, treatment must not have been yet initiated before inclusion (except surgical excision).
• In case of metastatic disease, project of new line of systemic treatment must have been decided before inclusion.
• Patient followed in the center within a standard of care procedure or clinical trial.
• Archived tumor specimen at initial diagnosis available (before treatment initiation).
• Evaluable disease (measurable as per RECIST 1.1) or not.
• ECOG Performance status 0-3.
• Patient able to participate and willing to give informed consent prior to performance of any study-related procedures.
• Patient affiliated to a Social Health Insurance in France.

You may not qualify if…

• Diagnosis of all other histotypes of soft tissue sarcoma.
• Any condition contraindicated with procedures required by the protocol.
• Known history of positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
• Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
• Pregnant or breast-feeding woman.
• Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Where it is running

• Chu Besancon - Site Jean Minjoz — Besançon, France (enrolling)
• Institut Bergonié — Bordeaux, France (enrolling)
• Centre Jean Perrin — Clermont-Ferrand, France (enrolling)
• Centre Antoine Lacassagne — Nice, France (enrolling)
• Institut Godinot — Reims, France (enrolling)
• Centre Eugene Marquis — Rennes, France (enrolling)
• Hôpital Cochin - Site Port-Royal — Paris, France (enrolling)
• Hôpitaux Universitaires de Strasbourg — Strasbourg, France (enrolling)
• Institut Universitaire du Cancer Toulouse - Oncopole — Toulouse, France (enrolling)
• Institut de Cancerologie de Lorraine — Vandœuvre-lès-Nancy, France (enrolling)
• Institut Curie — Paris, France (enrolling)
• Centre Oscar Lambret — Lille, France (enrolling)
• Chu Dupuytren — Limoges, France (enrolling)
• Centre Leon Berard — Lyon, France (enrolling)
• Chu Poitiers — Poitiers, France (enrolling)
• Chu de Marseille - Hopital de La Timone — Marseille, France (enrolling)
• Centre Georges François Leclerc — Dijon, France
• Institut de Cancerologie de L'Ouest - Site Rene Gauducheau — Saint-Herblain, France
• Institut Gustave Roussy — Villejuif, France
• Institut Paoli-Calmettes — Marseille, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.